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Background: The aim of this study was to evaluate postoperative complications in 
patients having major elective surgery using Oesophageal Doppler Monitor (ODM) 
guided Goal-Directed Hemodynamic Therapy (GDHT), in which administration of fluids, 
inotropes, and vasopressors was guided by stroke volume (SV), mean arterial pressure 
(MAP), and cardiac index (CI). 
Methods: This was a prospective, multicentre, randomized, parallel-group, controlled 
patient- and observer-blind trial (ISRCTN93543537) conducted in adults scheduled for 
major elective surgery. Randomization and allocation were carried out by central 
computer system. In the control group, intraoperative fluids were given based on 
traditional principles. In the GDHT group, the intraoperative goals were to maintain a 
maximal SV, with MAP > 70mmHg, and CI  2.5 L*min-1*m-2. The primary outcome was 
percentage of patients with postoperative complications during the first 180 days after 
surgery.  
Results: 450 patients were randomized to the GDHT group (n=224) or to the control 
group (n=226). Data from 428 patients were analysed. The percentage of patients with 
complications was significantly lower in the GDHT group (15% vs.27.6% p=0.001). There 
were also fewer specific complications (acute kidney disease, pulmonary oedema, 
respiratory distress syndrome, wound infections etc), and the length of hospital stay was 
shorter in the GDHT group. 
Conclusions: ODM-guided GDHT using SV, CI and MAP decreased postoperative 






























Approximately 240 million anaesthesia procedures are performed annually worldwide1. 
Of these, approximately 10% are in high-risk patients. Although there is no consensus 
on the definition of “high-risk” patients2, this group of patients probably accounts for 
more than 80% of perioperative deaths3. Moderate-risk surgery is much more common 
and constitutes about 40% of total surgical procedures. Nearly 30% of moderate-risk 
surgical patients experience minor postoperative complications, most often affecting 
gastrointestinal tract, and including delayed enteral feeding, paralytic ileus, nausea or 
vomiting, and wound complications4. Even minor complications prolong hospital stay5 
and increase healthcare costs6,  and, more importantly, can reduce long-term survival7. 
The European Surgical Outcomes Study (EUSOS) in patients having non-cardiac surgery 
concluded that in-hospital mortality rate was high (4%) and varies substantially among 
European countries8. There were also large differences in post-surgery mortality among 
hospitals within each country, suggesting that there is a potential to improve survival 
after surgery9 10. Many postoperative complications are thought to be related to tissue 
hypoperfusion and an imbalance between oxygen delivery and consumption11. 
Perioperative fluid management strongly influences patient outcomes12–14. 
Paradoxically, despite existence of national guidelines15 16 and international 
recommendations17–20, there remains wide variability in hemodynamic monitoring21 
and type and volume of administered fluids22 23.  
Goal-directed hemodynamic therapy (GDHT) is a method aiming at optimal dosing and 
timing of fluids, inotropes, and vasopressors through monitoring of cardiac output (CO) 
and other hemodynamic parameters. Various studies suggested that GDHT helps 
prevent organ hypoperfusion and fluid overload, thereby reducing the rate of 
postoperative complications24. However, the OPTIMISE trial12 and other recent 
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studies25–27 suggested that the benefits associated with GDHT may be lower than 
previously reported, and that GDHT may even worsen patient outcomes if combined 
with a liberal maintenance regimen28. In particular, the usefulness of Oesophageal 
Doppler monitoring to guide GDHT has recently been questioned29 30.  
We carried out a controlled randomized clinical trial to study the effect of ODM-guided 
administration of intravenous fluids and vasopressor and inotropic drugs on 
postoperative complications after major surgery.  Specifically, we tested the hypothesis 




This was a randomized controlled clinical trial performed at 5 centres in Spain between 
2011 and 2014. Patients were recruited at Hospital Universitario Infanta Leonor, 
Madrid; Hospital Universitario Ramón y Cajal, Madrid; Hospital Clínico Universitario 
Lozano Blesa, Zaragoza; Hospital de Vinalopó, Alicante; and Hospital de Torrevieja, 
Alicante. Unidad Española de Evaluaciones Sanitarias (Agencia Laín Entralgo, Madrid, 
Spain) supported this study, approved by the Ethics Committee of the Hospital 
Universitario Gregorio Marañón, Madrid (HUIL 2011-02-22), and registered by the 
principal investigator (JMCV) in the primary clinical trial registry ISRCTN 
(ISRCTN93543537). The Ethics Committee at each centre approved the study protocol; 
the trial was conducted according to the original protocol, which remained unchanged 
throughout the duration of the trial. The full study protocol (in Spanish) is available upon 
request, and the summarized English version can be accessed at 
http://www.eargroup.es/. 
The manufacturer of the ODM system used for CO monitoring (Deltex Medical Ltd., 
Chichester, United Kingdom) provided training to all investigators before the start of the 
clinical trial. Written informed consent was obtained from all patients prior to surgery. 
Principal investigators (JMC and SAL) performed site visits for source data verification.   
 
Study population 
Eligible patients were subjects of 18 years of age or older and scheduled for major 
abdominal, urological, gynaecological, or orthopaedic surgery under general 
anaesthesia, using laparoscopic or open approaches. Surgery was considered major if it 
fulfilled at least one of the following criteria: expected duration ≥2 hours, estimated 
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blood loss greater than 15% of blood volume, transfusion requirements of at least 2 
packs of red blood cells. Exclusion criteria were emergency surgery, American Society of 
Anaesthesiology (ASA) patient classification status31 exceeding III, contraindications for 
ODM monitoring, or aortic pathology that could lead to misinterpretation of 
hemodynamic variables (i.e., intra-aortic balloon pumping, or aneurysms of the thoracic 
aorta). The principal investigator at each site evaluated eligibility, obtained informed 
consent, and enrolled participants. 
 
Study design 
This was a randomized, controlled, multicentre, parallel-arm, patient- and observer-
blind superiority trial. Randomization was performed through a secure web-based 
system provided by ‘Agencia Laín Entralgo’ (Madrid, Spain). Eligible participants were 
randomized 1:1 ratio to the intervention or control groups. Allocation details were 
concealed in sequentially numbered, opaque, sealed and stapled envelopes. The 
envelopes were opened by the investigator on the day of surgery, when patients were 
randomized. Patients and physicians who collected data and evaluated patients during 
the postoperative period were blinded to the treatment allocation. However, it was 
impossible to blind the researchers who performed hemodynamic monitoring.  
All patients received balanced anaesthesia, intravenous anaesthetic induction, and 
neuromuscular relaxants; for pragmatic reasons, their administration was made at the 
discretion of the anaesthesiologist. Bispectral Index monitoring system (BIS, Medtronic, 
Dublin, Ireland) was used to monitor the depth of anaesthesia. Sevoflurane was used 
for anaesthesia maintenance, with the target range of BIS values between 40-60. 
Epidural anaesthesia, central venous catheter placement and invasive radial arterial 
 11 
blood pressure monitoring were performed per preference of the anaesthesiologist. All 
patients had basic anaesthetic monitoring with five-lead-electrocardiogram, pulse 
oximetry, and oscillometric blood pressure; at least one peripheral intravenous line was 
established. All patients received standard measures to maintain oxygen saturation by 
pulse oximetry ≥ 94%, normothermia, and heart rate (<100 beats min-1). Ventilation with 
inspired oxygen fraction of 60% was mechanically controlled to maintain P arterial CO2 
between 35 and 45 mmHg, with a positive end-expiratory pressure of 4-6 mmHg and 
tidal volume of 6-8 ml kg-1. 
In both groups, blood loss was compensated for by infusion of colloid in a 1:1 ratio. 
Packed red cells were transfused when haemoglobin level was < 10 g dl-1 in patients with 
cardiac comorbidities, or below 7 g dl-1 in those without cardiac comorbidities).   
 
Control group 
During the intraoperative period, patients randomized to the control group received a 
continuous infusion of balanced crystalloid fluids (Ringer lactate) at an infusion rate of 
3-5 ml kg-1 h-1 in case of laparoscopic surgery, and 5-7 ml kg-1 h-1 in case of open surgery. 
They were also allowed to receive colloid solution (hydroxyethyl starch [HES] 6% 
130/0.4, Voluven®, Fresenius Kabi, Germany), vasopressors and inotropes based on the 
judgment of the anaesthesiologist in charge. Intraoperative treatment goals in the 
control arm were flexible to avoid both extremes of clinical practice and practice 
misalignment32. 
 
GDHT group  
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Patients in the intervention group were given intravenous fluids, vasopressors, and 
inotropes according to a hemodynamic algorithm as shown in Figure 1. Intraoperative 
hemodynamic monitoring was conducted using oesophageal Doppler (CardioQ, EDM; 
Deltex Medical, Inc., Chichester, UK). The hemodynamic protocol was initiated after 
insertion of the probe. At the beginning of surgery, patients received an initial 
hemodynamic assessment based on stroke volume (SV), cardiac index (CI) and mean 
arterial pressure (MAP). First, preload was optimized by crystalloid loading to achieve 
and maintain a maximal SV. In addition to routine fluid management, the patients were 
given 250 ml boluses of crystalloid solution. If the SV increased by 10% or more, the fluid 
challenge was repeated. If, after two crystalloid boluses, the patient required more 
fluids to optimize SV, colloid (HES) boluses were given. The fluid challenges of 250 ml 
were repeated until the SV failed to rise by 10%. At this point, the patient’s individual 
preload was considered optimized, and SV was determined and used as the 
hemodynamic goal until the end of surgery. No further colloid fluid boluses were given 
until a 10% decrease in SV occurred. In patients with no response to fluid challenge, 
inotropes were given to reach a minimum CI (2.5 l min-1 m-2), which served as a safety 
parameter to prevent low CO. If SV was optimized and CI was within the target range 
but MAP was below 65 mmHg, vasopressors were given. Every 5 minutes, patients were 
reassessed to maintain the values within the desired range, and hemodynamic data 
were recorded. The hemodynamic protocol started immediately after probe placement, 
and continued until the end of the surgery. At the end of surgery total catecholamine 





The primary end point was the percentage of patients who developed pre-defined 
postoperative complications in the 180 days after surgery, including complications that 
occurred before hospital discharge and those that happened after discharge and 
required ambulatory or in-hospital care. Data were obtained from patient history and 
by telephone follow-up at 180 days after surgery. Initial definition of postoperative 
complications was based on the guidelines of the American College of Surgeons National 
Surgical Quality Improvement Program (ACS NSQIP) published in 201133. However, after 
the standards for definitions and use of outcome measures for clinical effectiveness 
research in perioperative medicine (EPCO) guidelines34 were updated in 2014, the 
definition of postoperative complications in the study were updated to align with the 
new standards35, a change that was made before unblinding and data analysis. 
Secondary end points were: length of hospital stay (defined as the number of days spent 
in the hospital from the day of surgery to hospital discharge or death), length of stay in 
the intensive care unit, re-interventions, time to onset of oral tolerance and time to 
ambulation, and all-cause mortality at 180 days following surgery.  
Sociodemographic and clinical data, ASA physical status31, comorbidities, and 
preoperative haemoglobin were recorded at baseline. Functional status was described 
via metabolic energy equivalents (METS)36. 
Data were recorded in case report forms at each site by blinded investigators; 
postoperative data were obtained from clinical records completed by surgeons and 
anaesthesiologists responsible for patient care (blinded to the allocation). Data were 
uploaded in the database created for the study; this database could be accessed only by 
the trial principal investigator and the statistician (JMCV, CFP), who analysed the data.  
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Data validation was conducted by the principal investigator and an external advisor 




Sample size calculation was based on a meta-analysis of randomized clinical trials of 
ODM in colorectal resection, which reported a 30% incidence of complications in the 
ODM group, compared to 49% in the control group37. One hundred five patients per arm 
would be needed to detect a 19% difference in the incidence of complications between 
GDHT and control with a power of 80% and an alpha error of 0.05. We thus planned to 
recruit equal number of patients for each type of surgery (abdominal, urological, 
gynaecological, or orthopaedic), resulting in a total of 840 patients. Due to low 
recruitment, we decided to exclude “post hoc” the Orthopaedic subgroup for analysis 
of complications and their severity. 
The analysis was carried out on a modified intention to treat basis (all randomized 
patients who received the study treatment). Qualitative variables were described using 
frequency distribution, and quantitative variables were described by mean and standard 
deviation (SD) in case of normal distribution or median and interquartile range (IQR) in 
case of asymmetric distribution. 
Potential confounders were selected to adjust the primary effect of the study. The 
primary outcome was expressed as percentage of patients with postoperative 
complications in each group. Odds ratios and 95% confidence intervals (95% CI), both 
univariate and adjusted to a logistic model with bootstrap estimate, were calculated. 
Each complication was classified as type 0, 1, 2 or 3 depending on its severity according 
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to the EPCO guidelines34, describing the severity reached as mean and standard 
deviation and analyzed by Student’s T test. Quantitative secondary objectives were 
assessed using Mann-Whitney nonparametric test. For all statistical tests, the 
significance level was set to 0.05. Calculations were performed using JMP 13.1 and R 
3.3.2 statistical packages. An interim analysis was performed at the halfway point. No 




A total of 450 patients were enrolled, and 428 were randomized between 2011 and 
2014. Two hundred twenty-four patients were allocated to the GDHT algorithm, and 226 
to the standard care. Twenty-two patients did not receive study treatment and were not 
included in the analysis (Figure 2). There were no cases of lost-to-follow-up. The 
resolution of the Committee on Pharmacovigilance Risk Assessment (PRAC) of the 
European Medicines Agency (EMA) / 606.303 of October 201338, recommended not to 
use 6% HES in septic, burned and critically ill patients, as well as in clinical trials and in 
situations of hypovolemia39. The confusion generated by the restrictions in the use of 
HES led to a major decrease in recruitment, since HES was the only colloid permitted by 
the study protocol. Because of the drop in recruitment we were forced to stop the trial 
in 2014. Thus, only 214 patients per arm (GDHT or control, with the 4 types of surgery 
pooled together) were included.  
Baseline patient characteristics were similar between the groups (Table 1), although 
there were more patients with diabetes mellitus, chronic obstructive pulmonary 
disease, and chronic alcohol consumption in the GDHT arm (Table 1). There were more 
patients with ASA physiological status III in the GDHT group. Mean surgery duration was 
similar between the two groups. Most of the study patients were undergoing major 
gastrointestinal surgery, while the number of those undergoing orthopaedic surgery was 
relatively small. Distribution of patients between the surgery categories and approaches 
was similar in the two arms (Table 2).  
Only one patient suffered nasal trauma with epistaxis caused by nasal insertion of the 
oesophageal probe. 
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The percentage of patients who experienced complications was lower in the GDHT 
group than in control group [14.95% vs. 27.6%, p=0.001, Odds Ratio = 0.46 (95% CI: 0.29-
0.75; relative risk reduction = 45.7%, Figure 3], as well as the severity of complications 
were also lower (Figure 4). There were significant fewer patients with acute kidney 
injury (AKI), acute respiratory distress syndrome, acute pulmonary oedema, pneumonia, 
and superficial and deep surgical site infection in the GDHT group. No significant 
differences in other analysed complications were observed. Notably, we found no 
significant difference in the incidence of anastomotic breakdown between the groups 
[3 (1.4%) patients in the GDHT group versus 8 (3.7%) patients in the control group]. The 
“post hoc” exclusion of the orthopaedic subgroup did not modify the analysis results 
(Figure 3 and 4). 
Analysis of secondary outcomes revealed a significant reduction in length of hospital 
stay (p=0.002), length of UCI stay (p<0.001), length of complication-related hospital stay 
(p=0.01), time to onset of oral tolerance (p<0.001) and time to ambulation (p<0.001) in 
the GDHT group (Figure 5). There was no significant difference in the percentage of 
patients that were re-operated [13 (6%) patients in the GDHT group versus 25 (11.6%) 
patients in the control group], or in all-cause mortality at 180 days of follow-up [10 
(4.6%) patients in the GDHT group versus 9 (4.25%) patients in the control group]. Blood 
losses and overall volume of intra-venous colloid and crystalloid fluids infused during 
the intraoperative period was similar the GDHT and control groups. Volume of fluids 
administered postoperatively, as well as use of vasoactive drugs (norepinephrine and 




Use of a hemodynamic optimization algorithm for management of low-moderate risk 
patients having major abdominal surgery significantly reduced postoperative 
complications in the 180 days after surgery. There was a decrease in AKI, acute 
respiratory distress syndrome, acute pulmonary oedema, pneumonia, and superficial 
and deep surgical site infection. Moreover, length of hospital stay was shortened, 
although no differences in mortality at 180 days after surgery were found. 
Hemodynamic monitoring and responsive fluid administration are supposed to allow for 
early detection of warning signs and for prompt problem rectification thus preventing 
organ damage related to inadequate oxygen supply. Adjustments in the administration 
of fluids and drugs must be performed in a timely manner to avoid both insufficient 
organ perfusion and fluid overload40. Numerous trials and meta-analyses showed that a 
goal-directed approach of haemodynamic optimisation reduces postoperative 
complications and mortality in high-risk surgical patients12 41 42, regardless of the choice 
of monitoring method or target variables43–45. However, a recent meta-analysis and 
several trials26 30 46, suggested that the GDHT benefits might be less pronounced than 
previously believed, especially in low-moderate risk patients. Thus, the question of 
whether GDHT improves postoperative outcomes is still under debate47–49. In addition, 
it should be noted that previous studies12 28 analyzed moderate or severe complications, 
while low-severity complications were not considered. In our study, although we also 
found a statistically significant decrease in moderate-severe complications, most of the 
complications that occurred were low-severity. 
Several reasons could explain the observed discrepancies between different trials. One 
of them is ample differences in trial design, patient populations, hemodynamic 
protocols in the intervention groups and standard of care in the control groups. The 
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other reason in many cases is low sample size and insufficient statistical power to 
demonstrate the differences. Thus, for instance, in studies by Pearse et al. and Pestaña 
et al., the researchers found a decrease in the complication incidence in the GDHT 
group, but it was not statistically significant12 25.  
In our study, there were significantly fewer patients with AKI in the intervention group, 
despite similar net amounts of perioperative fluids, both crystalloid and colloid, and no 
differences in the number of patients intraoperatively treated with vasopressors and 
inotropes. Several studies showed that GDHT decreases the incidence of postoperative 
AKI50, including when, as in our study, the amounts of perioperative fluids administered 
to intervention and control arms were similar51. This suggests that the benefits of GDHT 
could be attributed not only to providing additional fluids where required, but also to 
guided and responsive fluid usage and to avoiding unnecessary fluid delivery when 
hemodynamic objectives are met52.   
While there is a general agreement that GDHT is beneficial in high-risk surgical patients41 
53 the use of GDHT in surgical patients with low-moderate risk is still controversial14 54. 
SV optimization could lead to fluid overload28 (24), especially in cases with a liberal fluid 
maintenance46. A systematic review55 and recent randomized controlled trials 
demonstrated that liberal administration of ﬂuid and salt could be deleterious 
compared to a more restrictive regimen56 57. Many centres now recommend a baseline 
intraoperative crystalloid regimen of 1.5ml kg-1 h−1 17. Against this background, our trial 
could be criticized for an excessively liberal standard ﬂuid regimen. Indeed, we used a 
fluid maintenance currently considered liberal28, however, it was more restrictive than 
what was considered liberal when the study was initiated (perioperative infusion greater 
than 5 litres/24 hours)28 46. Although GDHT allows for personalized titration of 
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intraoperative intravenous ﬂuids, it is possible that aiming at a neutral perioperative 
ﬂuid balance is adequate for patients with sufficient physiological reserve to correct 
minor disturbances in homeostasis. 
Although retrospective studies with a similar algorithm have been conducted in the 
past58, this is, to our knowledge, the first randomized controlled clinical trial where 
vasopressor and inotropic treatment were incorporated as security measures to treat 
episodes of hypotension or low CI in patients with optimized SV. Our results are 
consistent with previous studies in which the CI was used as a target (54) or as a safety 
measure44. A recent review and meta-analysis also concluded that outcomes were 
improved when vasopressors and inotropes were incorporated in the hemodynamic 
algorithm59. SV hemodynamic optimization proved superior to CI optimization when 
haemorrhagic shock was induced in experimental animals60.  
Infectious complications were significantly reduced in the GDHT group. These findings 
are consistent with a recent meta-analysis demonstrating that GDHT reduced surgical 
site infections and pneumonia61. Despite fewer patients with complications mortality 
was similar at 180 days. Nonetheless, it is possible that a longer-term follow-up would 
help to reveal an effect on post-surgery deaths53. 
The strengths of the study include its randomized and controlled nature and large 
sample size. To our knowledge, this is one of the largest controlled clinical trials on ODM-
guided GDHT. Our pragmatic approach increases its external validity by approximating 
routine clinical practice. 
Our study has also limitations. First, the person performing intraoperative hemodynamic 
monitoring was not blinded. To compensate for this, blinded researchers performed 
data collection and followed the patients after the surgery. Second, although the 
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outcomes were properly pre-defined, it is possible that some subjectively perceived 
postoperative complications might have been underestimated due to intrinsically less 
accurate analysis. Third, the postoperative fluid management in the ICU was not 
standardized. Although overall postoperative ﬂuid volumes infused were similar, we do 
not have details about exact timing of ﬂuid administration cannot exclude the possibility 
that poor postoperative ﬂuid management skewed the effects of intraoperative ﬂuid 
optimization. Forth, the discharge criteria were not predefined in our study, which can 
limit the interpretation of length of stay parameters. Undoubtedly, length of hospital 
stay is an important factor for the patient and for the healthcare system. However, it is 
obvious that it is affected by many aspects besides postoperative complications, 
including patients’ preoperative fitness and health, but also the social, structural, and 
logistical aspects of each individual patient and each health care system. Finally, 
although recruiting large groups of patients undergoing different types of surgery was 
initially planned, the actual patient population was largely composed of abdominal 
surgery patients, with only few subjects undergoing orthopaedic surgery. Thus, to clarify 
the effect of GDHT in urological, gynaecological, and orthopaedic surgery patients, 







The use of ODM-guided hemodynamic algorithm reduced the incidence of 
postoperative complications and length of hospital stay in adult patients having major 
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